Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gross Profit (2020 - 2025)

Harmony Biosciences Holdings' Gross Profit history spans 6 years, with the latest figure at $175.2 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 19.32% year-over-year to $175.2 million; the TTM value through Dec 2025 reached $670.1 million, up 20.11%, while the annual FY2025 figure was $670.1 million, 20.11% up from the prior year.
  • Gross Profit for Q4 2025 was $175.2 million at Harmony Biosciences Holdings, down from $179.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $179.8 million in Q3 2025 and bottomed at $49.3 million in Q1 2021.
  • The 5-year median for Gross Profit is $117.2 million (2023), against an average of $114.7 million.
  • The largest annual shift saw Gross Profit soared 201.02% in 2021 before it increased 11.95% in 2024.
  • A 5-year view of Gross Profit shows it stood at $73.4 million in 2021, then surged by 38.19% to $101.4 million in 2022, then grew by 23.5% to $125.3 million in 2023, then increased by 17.24% to $146.9 million in 2024, then increased by 19.32% to $175.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Gross Profit are $175.2 million (Q4 2025), $179.8 million (Q3 2025), and $162.3 million (Q2 2025).